IOVA vs NVS
IOVA: Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | IOVA | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $8.29 | $158.86 | |
| Market cap as of 2026-08-24 | $3.8B | $227.4B | |
| P/E as of 2026-08-24 | n/a | 21.95 | |
| PEG as of 2026-08-24 | n/a | 3.66 | |
| Net margin as of 2026-08-24 | -89.1% | +22.5% | NVS higher |
| Gross margin as of 2026-08-24 | +48.4% | +75.0% | NVS higher |
| Operating margin as of 2026-08-24 | -92.7% | +29.9% | NVS higher |
| ROE as of 2026-08-24 | -40.5% | +29.9% | NVS higher |
| ROA as of 2026-08-24 | -31.6% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-24 | 0.00 | 1.18 | IOVA lower |
| Revenue growth (YoY) as of 2026-08-24 | +34.5% | +3.3% | IOVA higher |
| Revenue CAGR (3y) SEC XBRL | +1388.7% | n/a | |
| Dividend yield as of 2026-08-24 | n/a | +3.7% | |
| Beta as of 2026-08-24 | 0.85 | 1.17 | |
| 1-year return as of 2026-08-21 close | +226.4% | +25.3% | IOVA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.